Version 1
: Received: 18 September 2024 / Approved: 19 September 2024 / Online: 19 September 2024 (11:49:59 CEST)
Version 2
: Received: 7 October 2024 / Approved: 8 October 2024 / Online: 8 October 2024 (13:44:17 CEST)
How to cite:
Yuyu, X.; Huiling, S. Possible Mechanisms and Strategies for Immune Therapy Resistance in Gastric Cancer. Preprints2024, 2024091478. https://doi.org/10.20944/preprints202409.1478.v1
Yuyu, X.; Huiling, S. Possible Mechanisms and Strategies for Immune Therapy Resistance in Gastric Cancer. Preprints 2024, 2024091478. https://doi.org/10.20944/preprints202409.1478.v1
Yuyu, X.; Huiling, S. Possible Mechanisms and Strategies for Immune Therapy Resistance in Gastric Cancer. Preprints2024, 2024091478. https://doi.org/10.20944/preprints202409.1478.v1
APA Style
Yuyu, X., & Huiling, S. (2024). Possible Mechanisms and Strategies for Immune Therapy Resistance in Gastric Cancer. Preprints. https://doi.org/10.20944/preprints202409.1478.v1
Chicago/Turabian Style
Yuyu, X. and Shen Huiling. 2024 "Possible Mechanisms and Strategies for Immune Therapy Resistance in Gastric Cancer" Preprints. https://doi.org/10.20944/preprints202409.1478.v1
Abstract
Gastric cancer has become one of the most common cancers in the world.Immunotherapy, especially immune point inhibitors targeting programmed cell death 1 or its ligand PD-L1, has been successfully applied in the clinical treatment of GC. However, only a small number of cancer patients experience persistent clinical responses during immunotherapy. In this review, we discussed the current status of immunotherapy for colorectal cancer, elucidated the mechanisms mediating immunotherapy resistance, predicted biomarkers for immunotherapy resistance, and strategies for improving immunotherapy efficacy.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.